Verastem Inc said it would wind down studies testing VS-6063, its lead therapy in development, to treat mesothelioma cancer, raising questions about the therapy’s potential to treat other forms of cancers. The company’s shares plunged as much as 63.7 percent to a record low in heavy trading on Monday.
